The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial

Heart

Volumn 94, Issue 6, 2008, Pages 717-723

  Henriksson, Martin ^a,b   Epstein, D M ^a   Palmer, S J ^a   Sculpher, M J ^a   Clayton, T C ^c   Pocock, S J ^c   Henderson, R A ^d   Buxton, M J ^e   Fox, K A A ^f  

^a UNIVERSITY OF YORK   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e BRUNEL UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; EARLY INTERVENTION; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; CORONARY ANGIOGRAPHY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44349186142     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.127340     Document Type: Article

References (26)

1. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908-17.
2. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005;366:914-20.
3. Kim J, Henderson RA, Pocock SJ, et al. Health-related guality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: one-year results of the third Randomized Intervention Trial of unstable Angina (RITA-3). J Am Coll Cardiol 2005;45:221-8.
4. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE, 2004.
5. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360:743-51.
6. Collet D. Modelling survival data in medical research. London: Chapman & Hall, 1994:107-47.
7. Government Actuary Department. Interim life tables. Expectation of life for males in the United Kingdom, based on data for the years 2002-2004. http://www.gad.gov.uk (accessed 21 Oct 2006).
8. National Statistics. Review of the registrar general on deaths by cause, sex and age, in England and Wales. London: National Statistics, 2003.
9. Epstein DM, Sculpher MJ, Clayton TC, et al. Costs of an early intervention versus a conservative strategy in acute coronary syndrome. Int J Cardiol. Published Online First: 17 August 2007.
10. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
11. Dolan P. Modeling valuations for EuroQol health states. Medical Care 1997;35:1095-108.
12. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996;9:113-20.
13. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64.
14. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002;360:711-5.
15. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J 2002;23:230-8.
16. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
17. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353:1095-104.
18. Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006;368:998-1004.
19. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.
20. McCullough PA, O'Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. J Am Coll Cardiol 1998;32:596-605.
21. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
22. Briggs A, Mihaylova B, Sculpher M, et al. Cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA Study. Heart 2007;93:1015-6.
23. Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145-8.
24. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 2002;288:1851-8.
25. Janzon M, Levin LA, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during Instability in Coronary artery disease. Eur Heart J 2002;23:31-40.
26. Janzon M. Treatment strategies in unstable coronary artery disease, economic and quality of life evaluations [dissertation]. Medical dissertation No. 811: Linköping University, 2003:1-176.